Scientific Sessions 2024  /  Featured Science: Vascular Outcomes in the Spotlight  /  Discussant: ONCO PE Trial
Logo

American Heart Association

  107
  0

Final ID:

Discussant: ONCO PE Trial

  • Kadian, Daniella  ( Mount Sinai , New York City , New York , United States )
  • Casanegra, Ana  ( MAYO CLINIC , Rochester , Minnesota , United States )
  • Okwuosa, Tochi  ( RUSH UNIVERSITY , Chicago , Illinois , United States )
    • Author Disclosures:
    Daniella Kadian: DO have relevant financial relationships ; Consultant:Boston Scientific:Active (exists now) ; Speaker:Medscape:Active (exists now) ; Speaker:Women As One:Past (completed) ; Executive Role:Society for Vascular Medicine:Active (exists now) ; Executive Role:CLI Global Society:Active (exists now) ; Research Funding (PI or named investigator):Philips Healthcare:Past (completed) ; Speaker:Abbott Laboratories:Active (exists now) | Ana Casanegra: DO NOT have relevant financial relationships | Tochi Okwuosa: DO have relevant financial relationships ; Consultant:ANTEV:Past (completed)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Featured Science: Vascular Outcomes in the Spotlight

Monday, 11/18/2024 , 08:00AM - 09:15AM

Featured Science

More abstracts on this topic:
Discussant

Hamburg Naomi

Rivaroxaban for 18 Months versus 6 Months in Cancer Patients with Low-risk Pulmonary Embolism: ONCO PE Trial

Yamashita Yugo, Morimoto Takeshi, Muraoka Nao, Shioyama Wataru, Chatani Ryuki, Shibata Tatsuhiro, Nishimoto Yuji, Ono Koh, Kimura Takeshi

More abstracts from these authors:
Panelist 4

Kadian Daniella, Leleiko Rebecca

Genetics of FMD and SCAD: Where we are and where we need to go

Kovacic Jason, Saw Jacqueline, Ganesh Santhi, Kadian Daniella

You have to be authorized to contact abstract author. Please, Login
Not Available